A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

NCT02324257 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: RO6958688
DRUG: Obinutuzumab
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche